KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Cost of Revenue

Last Annual Value

13.00K

3-Year CAGR

%

5-Year CAGR

-29%

10-Year CAGR

-16%

KT

Kalaris Therapeutics Inc Competitors Analysis of Cost of Revenue

KLRS · NASDAQ
CompanyCost of Revenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
13.00K
N/A-59.0%N/A 
300.00K
N/AN/AN/A
2.60M
N/AN/AN/A
3.69M
-3.0%21.7%N/A
124.66K
N/AN/AN/A
5.32M
-61.7%68.9%N/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
1.13M
144.8%N/AN/A
21.00K
N/AN/AN/A
1.99M
N/AN/A15.0%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7